Teva and Mylan get green light to launch Novartis generics

Pharmaceutical companies Teva and Mylan have each been granted permission to market a generic version of Novartis’s blood pressure treatment Diovan (valsartan) in the US.

In a statement on their websites, Israel-based Teva and US company Mylan said the US Food and Drug Administration had approved the launches following Abbreviated New Drug Applications from both companies.

Diovan, which is marketed by Novartis and is taken as a tablet, had US sales worth approximately $1.8 billion over the 12-month period ending on September 30, 2014, according to healthcare information website IMS healthcare.

According to a statement on Mylan’s website, both generic versions of the drug will be available in 40 mg, 80 mg, 160 mg, and 320 mg tablets.